$1.82

-0.19 (-9.45%)

11/20/2008 4:00 PM

Indevus Pharmaceuticals (IDEV)

CAPS Rating:

A biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men's health conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating IDEV

Add Stock to Watchlist

What the Community Thinks

Total Members

184 Outperforms

7 Underperforms

All-Stars

25 Outperforms

4 Underperforms

Wall Street

8 Outperforms

0 Underperforms

Members bullish on IDEV are also bullish on:

Members bearish on IDEV are also bearish on:

Ticker Tags

Micro Cap (4968), Biotechnology (230)
Suggest a tag

Indevus Pharmaceuticals At A Glance

Current Price:	$1.82
Last Trade Time:	11/20/2008 4:00 PM
Open:	$2.00
Previous Close:	$2.01
Daily Range:	$1.81 - $2.07
52-Week Range:	$1.19 - $7.70
Volume:	497,306
Market Cap:	$155.88M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

IDEV VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for IDEV

Indevus shares double on deals with FDA, Teva
9/26/2008 7:24:00 PM - AP
Movers roundup: F5 Networks, Wachovia
9/26/2008 2:41:00 PM - AP
Indevus shares double deals with FDA, Teva
9/26/2008 12:05:00 PM - AP
Indevus says bladder treatment gets US patent
8/13/2008 5:47:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

2 Indevus Pharmaceuticals (IDEV)

Avatar hwyman64 (< 20) Submitted: 9/29/08 9:23 AM

Looks like a big bandwagon

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 25 : 1 2 3 4 5 Next »

Recs 0 (IDEV) mellster (45.29) Submitted: 10/30/08 1:20 PM : Start Price: $2.11 IDEV Score: 0.33 Lots of drugs on the market already that generate substantial revenues, Nebido (blockbuster testosterone drug) approval in reach, Pagoclone and Valstar updates in the near-term are likely. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 2 (IDEV) hwyman64 (< 20) Submitted: 9/29/08 9:23 AM : Start Price: $3.20 IDEV Score: -6.43 Looks like a big bandwagon Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (IDEV) BernieRosa (< 20) Submitted: 9/27/08 12:25 PM : Start Price: $3.20 IDEV Score: -6.43 New patent FDA approval baby boomers needing pharma Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (IDEV) waewens (39.65) Submitted: 8/15/08 7:09 PM : Start Price: $2.09 IDEV Score: 29.23 Indevus Pharmaceuticals said Wednesday the drug Sanctura XR, which is used to treat overactive bladder, has received nearly 17 years worth of patent protection in the U.S. The patent issued by the U.S. government protects the once-a-day treatment through January 2025. The will have a good revenue stream because of the growth of older population using this drug because of overactive bladder. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (IDEV) wowdwarf (66.76) Submitted: 8/15/08 6:19 PM : Start Price: $2.09 IDEV Score: 29.23 looks like it will bounce to me Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 25 : 1 2 3 4 5 Next »

Wall Street

Results 1 - 8 of 8

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackLadenburg	54.28	08/06/08		NS	$1.75	+4.00%	-41.02%	+45.02
	TrackPacificGrow	< 20	01/30/08		NS	$6.42	-71.65%	-44.35%	-27.30
	TrackUBS	< 20	08/09/07		NS	$6.75	-73.04%	-48.82%	-24.21
	TrackRodmanRen	40.99	08/03/07		NS	$7.26	-74.93%	-48.77%	-26.16
	TrackJimCramer	87.74	03/23/07		3W	$6.62	-72.51%	-47.38%	-25.13
	TrackPZK	< 20	02/06/07		NS	$6.73	-72.96%	-47.95%	-25.00
	TrackJMP	< 20	12/08/06		NS	$7.96	-77.14%	-46.53%	-30.61
	TrackWedbush	< 20	09/08/06		NS	$6.07	-70.02%	-42.00%	-28.02

Results 1 - 8 of 8

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.